Febrile Neutropenia in Patients with Solid Tumors Undergoing Intravenous Chemotherapy

被引:5
|
作者
Moreira-Pinto, Joao [1 ]
Leao, Ines [2 ]
Palmela, Carolina [3 ]
Branco, Francisco [1 ]
Godinho, Joao [1 ]
Simoes, Pedro [1 ]
Leal-Costa, Luisa [1 ]
Lopes, Fabio [1 ]
Faria, Ana [1 ]
Casa-Nova, Mafalda [1 ]
Escaria, Ana [4 ]
Costa, Filipa [5 ]
Galvao, Isabel [6 ]
Teixeira, Jose [1 ]
Passos-Coelho, Jose Luis [1 ]
机构
[1] Hosp Beatriz Angelo, Med Oncol, Ave Carlos Teixeira 514, P-2674514 Loures, Portugal
[2] Ctr Hosp Vila Nova Gaia Espinho, Med Oncol, Vila Nova De Gaia, Portugal
[3] Hosp Beatriz Angelo, Gastroenterol, Loures, Portugal
[4] Hosp Beatriz Angelo, Syst Management, Loures, Portugal
[5] Hosp Beatriz Angelo, Pharm, Loures, Portugal
[6] Hosp Beatriz Angelo, Clin Pathol, Loures, Portugal
关键词
Chemotherapy; Complication management; Disease management; Supportive care; Febrile neutropenia; MORTALITY; CANCER; GUIDELINES; MANAGEMENT; CARE; HOSPITALIZATIONS; CONSEQUENCES; EPIDEMIOLOGY; IMPACT; COST;
D O I
10.1159/000506109
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Febrile neutropenia (FN) is a potentially life-threatening complication of systemic chemotherapy (CT) that often requires hospital admission. Delay in diagnosis and treatment are associated with higher morbidity and mortality. Objective: We aimed to determine the factors that influence FN episodes outcomes in the emergency room (ER). Methods: This was a retrospective study of all FN episodes (with a collected blood culture [BC]) that occurred between 2012 and 2016 at our institution. FN was defined as a temperature >= 38 degrees C and an absolute neutrophil count (ANC) <1,000/mu L, expected to decrease to <500/mu L in the following week. Results: Between 2012 and 2016, there were 173 FN episodes in 153/1,947 patients treated with intravenous CT. Most of these episodes (n = 121, 70%) were diagnosed in the ER, 29 in the outpatient clinic, and 23 as inpatients. In the ER, the median time was 36 min from hospital nurse triage to medical observation, and 52 min from medical observation to complete blood count specimen collection. There was a positive BC in 33 FN episodes, 72% with Gram-negative bacteria. A total of 160 FN episodes led to hospital admission and 13 were treated as outpatients. Mortality associated with the FN episode was 15% and an ANC <100/mu L was predictive of increased mortality. Conclusion: This study confirms that FN is a serious and common complication of IV CT which must be diagnosed and treated promptly. Profound neutropenia was the only predictive factor of mortality. (C) 2020 S. Karger AG, Basel
引用
收藏
页码:605 / 611
页数:7
相关论文
共 50 条
  • [1] Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors
    Lambertini, Matteo
    Ferreira, Arlindo R.
    Del Mastro, Lucia
    Danesi, Romano
    Pronzato, Paolo
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2015, 15 (12) : 1799 - 1817
  • [2] Current Status of Management of Febrile Neutropenia in Chemotherapy for Solid Tumors
    Ishikawa, Takashi
    Narui, Kazutaka
    Kaise, Hiroshi
    Tsugawa, Koichiro
    Ichikawa, Yasushi
    Sakamaki, Kentaro
    Mukai, Hirofumi
    ANNALS OF ONCOLOGY, 2016, 27
  • [3] Risk and Consequences of Chemotherapy-Induced Febrile Neutropenia in Patients With Metastatic Solid Tumors
    Weycker, Derek
    Li, Xiaoyan
    Edelsberg, John
    Barron, Rich
    Kartashov, Alex
    Xu, Hairong
    Lyman, Gary H.
    JOURNAL OF ONCOLOGY PRACTICE, 2015, 11 (01) : 47 - +
  • [4] Update on Febrile Neutropenia in Pediatric Oncological Patients Undergoing Chemotherapy
    Cennamo, Federica
    Masetti, Riccardo
    Largo, Prisca
    Argentiero, Alberto
    Pession, Andrea
    Esposito, Susanna
    CHILDREN-BASEL, 2021, 8 (12):
  • [5] Evaluation of Febrile Neutropenia in Hospitalized Patients with Neoplasia Undergoing Chemotherapy
    Bachlitzanaki, Maria
    Aletras, George
    Bachlitzanaki, Eirini
    Messaritakis, Ippokratis
    Koukias, Stergos
    Koulouridi, Asimina
    Bachlitzanakis, Emmanouil
    Kaloeidi, Eleni
    Vakonaki, Elena
    Kontopodis, Emmanouil
    Androulakis, Nikolaos
    Chamilos, Georgios
    Mavroudis, Dimitrios
    Ioannou, Petros
    Kofteridis, Diamantis
    MICROORGANISMS, 2023, 11 (10)
  • [6] Colony-stimulating factors in the prevention of solid tumors induced by chemotherapy in patients with febrile neutropenia
    Freyer, G
    Ligneau, B
    Trillet-Lenoir, V
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 1998, 10 (01) : 3 - 9
  • [7] ECONOMIC EVALUATION OF PEGFILGRASTIM AS PROPHYLAXIS FOR FEBRILE NEUTROPENIA IN PATIENTS WITH SOLID TUMORS OR LYMPHOMA RECEIVING CHEMOTHERAPY IN MEXICO
    Alva, M. E.
    Carlos, F.
    Espinosa, K.
    Barbosa, V
    Naranjo, M.
    VALUE IN HEALTH, 2015, 18 (07) : A459 - A460
  • [8] Assessment of procalcitonin as a diagnostic and prognostic marker in patients with solid tumors and febrile neutropenia
    Jimeno, A
    Garcia-Velasco, A
    del Val, O
    González-Billalabeitia, E
    Hernando, S
    Hernández, R
    Sánchez-Muñoz, A
    López-Martín, A
    Durán, I
    Robles, L
    Cortés-Funes, H
    Paz-Ares, L
    CANCER, 2004, 100 (11) : 2462 - 2469
  • [9] Risk Factors for Febrile Neutropenia in Children With Solid Tumors Treated With Cisplatin-based Chemotherapy
    Castelan-Martinez, Osvaldo D.
    Rodriguez-Islas, Felipe
    Vargas-Neri, Jessica L.
    Palomo-Colli, Miguel A.
    Lopez-Aguilar, Enrique
    Clark, Patricia
    Castaneda-Hernandez, Gilberto
    Rivas-Ruiz, Rodolfo
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2016, 38 (03) : 191 - 196
  • [10] The Potential Contribution of Dental Foci and Oral Mucositis to Febrile Neutropenia in Patients Treated With Myelosuppressive Chemotherapy for Solid Tumors and Lymphoma
    Zecha, Judith A. E. M.
    Raber-Durlacher, Judith E.
    Laheij, Alexa M. G. A.
    Westermann, Anneke M.
    de Lange, Jan
    Smeele, Ludi E.
    FRONTIERS IN ORAL HEALTH, 2022, 3